BioCryst Pharmaceuticals (BCRX)

Company

"BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases." (company website)

bcrx(1-1)
BCRX 4-month chart
bcrx(1-1)_1yr
BCRX 1-year chart

Buy

9 March 2010. Bought 500 at $7.05.

We'll see. The signals on this are definitely mixed. On the one hand, there is the developing triangle formation in the chart, a bullish sign, and the 50-day moving average has leveled out and is tending upward ever so slightly. There was a big earnings surprise in February, another hopeful sign. On the other hand, volume is steadily decreasing.

  • Percentage price oscillator (PPO) — gently edged above the signal line
  • Volume — decreasing steadily

Based on technical analysis, MarketEdge calls BCRX a "buy" in a "weak upward trend."

Sell

gain Bottom line
0%

15 March 2010. Sold 500 at $7.10.

My stop-loss order was triggered in this morning's sour market, closing this position with just enough gain to cover trading costs. I had been a bit dubious about BCRX due to the declining volumes, and, at least for now, that scepticism was well-founded.